Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Global Market Report 2026

Description

Glucagon-like peptide-1 (GLP-1) cardiometabolic expansion refers to the broadening role of GLP-1-targeted therapies beyond their initial metabolic applications into a wider range of cardiometabolic health areas. This expansion is driven by growing scientific and clinical evidence demonstrating the ability of GLP-1 pathway modulation to influence multiple interconnected physiological functions.

The primary drug types of glucagon-like peptide-1 (GLP-1) cardiometabolic expansion include glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic polypeptide or glucagon-like peptide-1 dual agonists, and glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide oral therapies. Glucagon-like peptide-1 receptor agonists refer to therapeutic agents that mimic the action of the GLP-1 hormone to improve metabolic and cardiovascular outcomes. These therapies are used across indications including heart failure with preserved ejection fraction, peripheral artery disease, cardiovascular risk reduction, non-alcoholic steatohepatitis, and chronic kidney disease and are utilized by end-users including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

Tariffs are influencing the GLP-1 cardiometabolic expansion market by increasing the cost of importing active pharmaceutical ingredients, biologic production equipment, and advanced drug delivery devices used in GLP-1 receptor agonist manufacturing. This is affecting pharmaceutical companies and specialty clinics across segments such as GLP-1 receptor agonists, dual agonist therapies, and injectable formulations, particularly in regions dependent on global biologics supply chains like Asia-Pacific and Latin America. Hospitals and specialty clinics are experiencing higher procurement costs, potentially slowing therapy adoption. However, tariffs are also encouraging local biomanufacturing investments, regional API production, and diversification of pharmaceutical supply chains, strengthening long-term resilience in cardiometabolic drug accessibility.

The glucagon-like peptide-1(GLP-1) cardiometabolic expansion market size has grown rapidly in recent years. It will grow from $51.8 billion in 2025 to $59.47 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to rising prevalence of type 2 diabetes, increasing obesity rates globally, development of early glp-1 receptor agonists, growing awareness of metabolic syndrome, expansion of endocrinology treatment guidelines.

The glucagon-like peptide-1(GLP-1) cardiometabolic expansion market size is expected to see rapid growth in the next few years. It will grow to $101.82 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of cardiometabolic indications beyond diabetes, increasing adoption of combination incretin therapies, growth in preventive cardiology approaches, rising healthcare focus on obesity-driven comorbidities, integration of precision medicine in metabolic disease treatment. Major trends in the forecast period include expansion of glp-1 therapies into cardiovascular and chronic kidney disease management, increasing adoption of combination incretin therapies for multi-target cardiometabolic control, rising use of glp-1 drugs in obesity-related cardiometabolic risk reduction programs, growth of real-world evidence studies validating long-term cardioprotective benefits of glp-1 agents, increasing integration of glp-1 therapies into digital chronic disease management platforms.

The rising obesity and diabetes prevalence is expected to propel the growth of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market going forward. Obesity and diabetes are chronic metabolic disorders that increase body fat levels and impair the body's ability to regulate blood glucose effectively. The rise in obesity and diabetes is increasing due to reduced physical activity and growing sedentary lifestyles across global populations. The prevalence of obesity and diabetes is increasing the demand for glucagon-like peptide-1 (GLP-1) cardiometabolic therapies, as these drugs help manage blood glucose levels, promote weight reduction, and improve overall cardiometabolic health. For instance, in September 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency responsible for disease prevention and health promotion, 23 US states reported adult obesity prevalence rates above 35% in 2023, compared to 22 states in 2022. Therefore, the rising obesity and diabetes prevalence is driving the growth of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market.

Major companies operating in the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market are focusing on developing innovative products such as dual and multi-agonist receptor drugs to enhance weight reduction outcomes, improve metabolic control, and expand therapeutic benefits beyond diabetes into cardiovascular and obesity-related disease management. Dual and multi-agonist receptor drugs refer to therapies that simultaneously activate two or more hormone receptors, including GLP-1, GIP, or glucagon receptors, to improve metabolic functions such as blood glucose regulation, weight loss, and energy balance. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, launched Zepbound (tirzepatide) in the United States for chronic weight management in adults with obesity or overweight with weight-related comorbidities. This marked the first approval of a dual GIP and GLP-1 receptor agonist for obesity, significantly expanding the GLP-1 cardiometabolic treatment landscape beyond diabetes into large-scale weight management and metabolic disease intervention.

In December 2024, Novo Holdings A/S, a Denmark-based life sciences investment company, acquired Catalent, Inc. for $16.5 billion. With this acquisition, Novo Holdings aims to strengthen production capabilities for Novo Nordisk A/S's GLP-1 obesity and diabetes therapies by securing critical fill-finish manufacturing facilities and expanding manufacturing capacity for incretin-based treatments. Catalent, Inc. is a US-based company specializing in fill-finish, formulation, peptide development, and production services for GLP-1 and other cardiometabolic drugs.

Major companies operating in the glucagon-like peptide-1(glp-1) cardiometabolic expansion market are Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Zealand Pharma A/S; Innovent Biologics Inc.; Huadong Medicine Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Sciwind Biosciences Co. Ltd.; Ascletis Pharma Inc.; F. Hoffmann-La Roche AG; Pfizer Inc.; Sanofi S.A.; Regeneron Pharmaceuticals Inc.; Eccogene Inc.; Gan & Lee Pharmaceuticals Co. Ltd.; Altimmune Inc.

North America was the largest region in the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glucagon-like peptide-1(GLP-1) cardiometabolic expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glucagon-like peptide-1(GLP-1) cardiometabolic expansion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glucagon-like peptide-1 (glp-1) cardiometabolic expansion market consists of semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, and lixisenatide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The glucagon-like peptide-1(glp-1) cardiometabolic expansion market research report is one of a series of new reports from The Business Research Company that provides glucagon-like peptide-1(glp-1) cardiometabolic expansion market statistics, including glucagon-like peptide-1(glp-1) cardiometabolic expansion industry global market size, regional shares, competitors with a glucagon-like peptide-1(glp-1) cardiometabolic expansion market share, detailed glucagon-like peptide-1(glp-1) cardiometabolic expansion market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide-1(glp-1) cardiometabolic expansion industry. This glucagon-like peptide-1(glp-1) cardiometabolic expansion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses glucagon-like peptide-1(glp-1) cardiometabolic expansion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glucagon-like peptide-1(glp-1) cardiometabolic expansion ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glucagon-like peptide-1(glp-1) cardiometabolic expansion market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Drug Type: Glucagon-Like Peptide-1 Receptor Agonists; Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists; Glucagon-Like Peptide-1 Or Glucose-Dependent Insulinotropic Polypeptide Oral Therapies
2) By Indication: Heart Failure With Preserved Ejection Fraction; Peripheral Artery Disease; Cardiovascular Risk Reduction; Non-Alcoholic Steatohepatitis; Chronic Kidney Disease
3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutes
Subsegments:
1) By Glucagon-Like Peptide-1 Receptor Agonists: Short-Acting Glucagon-Like Peptide-1 Receptor Agonists; Long-Acting Glucagon-Like Peptide-1 Receptor Agonists; Weekly Glucagon-Like Peptide-1 Receptor Agonists; Daily Glucagon-Like Peptide-1 Receptor Agonists
2) By Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists: Injectable Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists; Oral Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists; Long-Acting Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists
Companies Mentioned: Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Zealand Pharma A/S; Innovent Biologics Inc.; Huadong Medicine Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Sciwind Biosciences Co. Ltd.; Ascletis Pharma Inc.; F. Hoffmann-La Roche AG; Pfizer Inc.; Sanofi S.A.; Regeneron Pharmaceuticals Inc.; Eccogene Inc.; Gan & Lee Pharmaceuticals Co. Ltd.; Altimmune Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MG1CE01_G26Q2

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Sustainability, Climate Tech & Circular Economy
- 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Expansion Of GLP 1 Therapies Into Cardiovascular And Chronic Kidney Disease Management
- 4.2.2 Increasing Adoption Of Combination Incretin Therapies For Multi Target Cardiometabolic Control
- 4.2.3 Rising Use Of GLP 1 Drugs In Obesity Related Cardiometabolic Risk Reduction Programs
- 4.2.4 Growth Of Real World Evidence Studies Validating Long Term Cardioprotective Benefits Of GLP 1 Agents
- 4.2.5 Increasing Integration Of GLP 1 Therapies Into Digital Chronic Disease Management Platforms

5. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Specialty Clinics
5.3 Ambulatory Surgical Centers
5.4 Research Institutes
5.5 Others

6. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Size, Comparisons And Growth Rate Analysis
7.3. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Segmentation

9.1. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Glucagon-Like Peptide-1 Receptor Agonists, Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists, Glucagon-Like Peptide-1 Or Glucose-Dependent Insulinotropic Polypeptide Oral Therapies
9.2. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Heart Failure With Preserved Ejection Fraction, Peripheral Artery Disease, Cardiovascular Risk Reduction, Non-Alcoholic Steatohepatitis, Chronic Kidney Disease
9.3. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
9.4. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Sub-Segmentation Of Glucagon-Like Peptide-1 Receptor Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Short-Acting Glucagon-Like Peptide-1 Receptor Agonists, Long-Acting Glucagon-Like Peptide-1 Receptor Agonists, Weekly Glucagon-Like Peptide-1 Receptor Agonists, Daily Glucagon-Like Peptide-1 Receptor Agonists
9.5. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Sub-Segmentation Of Glucose-Dependent Insulinotropic Polypeptide Or Glucagon-Like Peptide-1 Dual Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injectable Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists, Oral Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists, Long-Acting Glucose-Dependent Insulinotropic Polypeptide And Glucagon-Like Peptide-1 Dual Agonists

10. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Regional And Country Analysis

10.1. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

11.1. Asia-Pacific Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

12.1. China Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

13.1. India Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

14.1. Japan Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

15.1. Australia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

16.1. Indonesia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

17.1. South Korea Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

18.1. Taiwan Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

19.1. South East Asia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

20.1. Western Europe Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

21.1. UK Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

22.1. Germany Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

23.1. France Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

24.1. Italy Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

25.1. Spain Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

26.1. Eastern Europe Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

27.1. Russia Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

28.1. North America Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

29.1. USA Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

30.1. Canada Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

31.1. South America Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

32.1. Brazil Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

33.1. Middle East Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

34.1. Africa Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Regulatory and Investment Landscape

36. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Competitive Landscape And Company Profiles

36.1. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Company Profiles
- 36.3.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Other Major And Innovative Companies

Teva Pharmaceutical Industries Ltd., Zealand Pharma A/S, Innovent Biologics Inc., Huadong Medicine Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Viking Therapeutics Inc., Structure Therapeutics Inc., Sciwind Biosciences Co. Ltd., Ascletis Pharma Inc., F. Hoffmann-La Roche AG, Pfizer Inc., Sanofi S.A., Regeneron Pharmaceuticals Inc., Eccogene Inc., Gan & Lee Pharmaceuticals Co. Ltd.

38. Global Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market

41. Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market High Potential Countries, Segments and Strategies

41.1 Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market In 2030 - Countries Offering Most New Opportunities
41.2 Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market In 2030 - Segments Offering Most New Opportunities
41.3 Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer